Triple antiplatelet therapy in acute coronary syndromes

Drugs

Volumn 71, Issue 13, 2011, Pages 1703-1719

  Valgimigli, Marco ^a   Minarelli, Monica ^a  

^a UNIVERSITY OF FERRARA   (Italy)

Author keywords

Abciximab; Antiplatelets; Aspirin; Cangrelor; Clopidogrel; Coronary artery disease; Elinogrel; Eptifibatide; GPIIb IIIa antagonists; Prasugrel; Ticagrelor; Tirofiban.

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; CANGRELOR; CD40 LIGAND; CLOPIDOGREL; ELINOGREL; FIBRINOGEN; GLUCOSE REGULATED PROTEIN 78; GLYCOPROTEIN IIB; GLYCOPROTEIN IIIA; IMMUNOGLOBULIN F(AB) FRAGMENT; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLATELET DERIVED GROWTH FACTOR; PRASUGREL; THROMBOXANE A2; TICAGRELOR; TICLOPIDINE; VON WILLEBRAND FACTOR;

ACUTE CORONARY SYNDROME; BLOOD FLOW; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LOADING DRUG DOSE; LUNG EMBOLISM; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; REVIEW; THROMBOCYTE AGGREGATION; UNSTABLE ANGINA PECTORIS;

ACUTE CORONARY SYNDROME; ASPIRIN; CLINICAL TRIALS AS TOPIC; DRUG THERAPY, COMBINATION; HUMANS; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; PRACTICE GUIDELINES AS TOPIC; SEVERITY OF ILLNESS INDEX; THIENOPYRIDINES;

ANGINA;

EID: 80052610859     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/11594100-000000000-00000     Document Type: Review

References (62)

1. Falk E. Coronary thrombosis: pathogenesis and clinical manifestations. Am J Cardiol 1991 Sep 3; 68 (7): B28-35
2. Davie EW. Biochemical and molecular aspects of the coagulation cascade. Thrombosis Haemost 1995 Jul; 74: 1-6
3. Theroux P, Fuster V. Acute coronary syndromes: unstable angina and non-Q wave myocardial infarction. Circulation 1998 Mar 31; 97: 1195-206 (Pubitemid 28152893)
4. Phillips DR, Charo IF, Parise LV, et al. The plateletmembrane glycoprotein IIb-IIIa complex. Blood 1988 Apr; 71: 831-43
5. Kabbani SS, Watkins MW, Ashikaga T, et al. Platelet reactivity characterised prospectively: a determinant of outcome 90 days after percutaneous coronary intervention. Circulation 2001 Jul 10; 104: 181-6 (Pubitemid 32655835)
6. Campo G, Valgimigli M, Gemmati D, et al. Value of platelet reactivity in predicting response to treatment and clinical outcome in patients undergoing primary coronary intervention: insights into the STRATEGY study. J Am Coll Cardiol 2006 Dec 5; 48 (11): 2178-85 (Pubitemid 44873056)
7. Heusch G, Schulz R, Baumgart D, et al.Coronarymicroembolization. Prog Cardiovasc Dis 2001 Nov-Dec; 44: 217-30
8. Skyschally A, Erbel R, Heusch G. Coronary microembolisation. Circ J 2003 Apr; 67: 279-86
9. Ito H, Okamura A, Iwakura K, et al. Myocardial perfusion patterns related to thrombolysis in myocardial infarction perfusion grades after coronary angioplasty in patients with acute anterior wall myocardial infarction. Circulation 1996 Jun 1; 93: 1993-9 (Pubitemid 26167228)
10. Vorchheimer DA, Becker R. Platelets in atherothrombosis. Mayo Clin Proc 2006 Jan; 81 (1): 59-68 (Pubitemid 43054319)
11. Henn V, Slupsky JR, Grä fe M, et al. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature 1998 Feb 5; 391 (6667): 591-4 (Pubitemid 28157601)
12. Valgimigli M, Agnoletti L, Curello S, et al. Serum from patients with acute coronary syndromes displays a proapoptotic effect on human endothelial cells: a possible link to pan-coronary syndromes. Circulation 2003 Jan 21; 107 (2): 264-70 (Pubitemid 36135222)
13. Valgimigli M, Ceconi C, Malagutti P, et al. Tumor necrosis factor-alpha receptor 1 is a major predictor of mortality and new-onset heart failure in patients with acute myocardial infarction: the Cytokine-Activation and Long-Term Prognosis in Myocardial Infarction (C-ALPHA) study. Circulation 2005 Feb 22; 111 (7): 863-70 (Pubitemid 40279887)
14. Bassand JP, Hamm CW, Ardissino D, et al. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. The Task Force for the Diagnosis and Treatment of Non-ST-Segment Elevation Acute Coronary Syndromes of the European Society of Cardiology. Eur Heart J 2007 Jul; 28: 1598-660
15. Wright RS, Anderson JL, Adams CD, et al. 2011 ACCF/AHA focused update incorporated into the ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in collaboration with the American Academy of Family Physicians, Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons. J Am Coll Cardiol 2011 May 10; 57 (19): e215-367
16. Van de Werf F, Bax J, Betriu A, et al. Management of acute myocardial infarction in patients presenting with STsegment elevation. Eur Heart J 2008 Dec; 29: 2909-45
17. Antman EM, Hand M, Armstrong PW, et al. 2007 focused update of the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Canadian Cardiovascular Society, American Academy of Family Physicians, American College of Cardiology, American Heart Association. J Am Coll Cardiol 2008 Jan 15; 51 (2): 210-47
18. European Association for Percutaneous Cardiovascular Interventions, Wijns W, Kolh P, et al. Guidelines on myocardial infarction. Eur Heart J 2010 Oct; 31 (20): 2501-55
19. Meadows TA, Bhatt DL. Clinical aspects of platelet inhibitors and thrombus formation. Circ Res 2007 May 11; 100 (9): 1261-75 (Pubitemid 46742917)
20. Vane JR. Inhibition of prostaglandin synthesis as a mechanism for aspirin-like drugs. Nature 1971 Jun 23; 231: 232-5
21. Smith JB, Willis AL. Aspirin selectively inhibits prostaglandin production in human platelets. Nature 1971 Jun 23; 231: 235-7
22. Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 2001 Aug 22-29; 286 (8): 954-9 (Pubitemid 33010342)
23. Geiger J, Brich J, Hö nig-Liedl P, et al. Specific impairment of human platelet P2Y(AC) ADP receptor-mediated signaling by the antiplatelet drug clopidogrel. Arterioscler Thromb Vasc Biol 1999 Aug; 19 (8): 2007-11 (Pubitemid 29379936)
24. Patti G, Colonna G, Pasceri V, et al. Randomized trial of high loading dose of clopidogrel for reduction of periprocedural myocardial infarction in patients undergoing coronary intervention: results from theARMYDA-2 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) study. Circulation 2005 Apr 26; 111 (16): 2099-106 (Pubitemid 40577905)
25. CURRENT-OASIS 7 Investigators, Mehta SR, Bassand JP, et al. Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. N Engl J Med 2010 Sep 2; 363 (10): 930-42
26. Mehta SR, Tanguay JF, Eikelboom JW, et al. Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomized factorial trial. Lancet 2010 Oct 9; 376 (9748): 1233-43
27. Quinn MJ, Fitzgerald DJ. Ticlopidine and clopidogrel. Circulation 1999 Oct 12; 100: 1667-72 (Pubitemid 29477278)
28. Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007 Nov 15; 357 (20): 2001-15 (Pubitemid 350106708)
29. Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009 Sep 10; 361: 1045-57
30. Topol EJ. Toward a new frontier in myocardial reperfusion therapy: emerging platelet preeminence. Circulation 1998 Jan 20; 97: 211-8 (Pubitemid 28124680)
31. Brown DL, Fann CS, Chang CJ. Effect of glycoprotein IIb/IIIa inhibitors on the individual components of composite endpoints used in clinical trials of unstable angina and non-Q-wave myocardial infarction. Cardiovasc Drugs Ther 2000 Jun; 14 (3): 253-8 (Pubitemid 30447227)
32. De Luca G, Suryapranata H, Stone GW, et al. Abciximab as adjunctive therapy to reperfusion in acute ST-segment elevation myocardial infarction: a meta-analysis of randomized trials. JAMA 2005 Apr 13; 293: 1759-65
33. Tcheng JE, Ellis SG, George BS, et al. Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin antiplatelet antibody Fab 7E3 in high-risk coronary angioplasty. Circulation 1994 Oct; 90 (4): 1757-64 (Pubitemid 24320922)
34. Charo IF, Scarborough RM, DuMée CP, et al. Pharmacodynamics of the GPIIb-IIIa antagonist Integrelin: phase I clinical studies in normal healthy volunteers. Circulation 1992; 86 (Suppl. I): I-260
35. Peerlinck K, De Lepeleire I, Goldberg M, et al. MK-383 (L-700,462), a selective nonpeptide platelet glycoprotein IIb/IIIa antagonist, is active in man. Circulation 1993 Oct; 88 (4 Pt 1): 1512-7 (Pubitemid 23296898)
36. Cox D. Oral GPIIb/IIIa antagonists: what went wrong? Curr Pharm Des 2004; 10 (14): 1587-96 (Pubitemid 38559770)
37. Suh JW, Lee SP, Park KW, et al. Multicenter randomized trial evaluating the efficacy of cilostazol on ischemic vascular complications after drug-eluting stent implantation for coronary heart disease: results of the CILON-T (influence of CILostazol-based triple antiplatelet therapy ON ischemic complication after drug-eluting stenT implantation) trial. J Am Coll Cardiol 2011 Jan 18; 57 (3): 280-9
38. Tomasello SD, Angiolillo DJ, Goto S. Inhibiting PAR-1 in the prevention and treatment of atherothrombotic events. Expert Opin Investig Drugs 2010 Dec; 19 (12): 1557-67
39. Angiolillo DJ, Capodanno D, Goto S. Platelet thrombin receptor antagonism and atherothrombosis. Eur Heart J 2010 Jan; 31 (1): 17-28
40. Heestermans AA, van Werkum JW, Taubert D, et al. Impaired bioavailability of clopidogrel in patients with a ST-segment elevation myocardial infarction. Thromb Res 2008 May 1; 122 (6): 776-81
41. Lenzen MJ, Boersma E, Bertrand ME, et al. Management and outcome of patients with established coronary artery disease: the Euro Heart Survey on coronary revascularization. Eur Heart J 2005 Jun; 26 (12): 1169-79 (Pubitemid 40863123)
42. Lopes RD, Peterson ED, Chen AY, et al. Antithrombotic strategy in non-ST-segment elevation myocardial infarction patients undergoing percutaneous coronary intervention: insights fromthe ACTION(Acute Coronary Treatment and Intervention Outcomes Network) Registry. JACC Cardiovasc Interv 2010 Jun; 3 (6): 669-77
43. van 't Hof AW, Ten Berg J, Heestermans T, et al. Prehospital initiation of tirofiban in patients with ST-elevation myocardial infarction undergoing primary angioplasty (On-TIME) 2: a multicentre, double-blind, randomized controlled trial. Lancet 2008 Aug 16; 372 (9638): 537-46
44. Le May MR, Wells GA, Glover CA, et al. Primary percutaneous coronary angioplasty with and without eptifibatide in ST-segment elevation myocardial infarction: a safety and efficacy study of integrilin-facilitated versus primary percutaneous coronary intervention in ST-segment elevation myocardial infarction (ASSIST). Circ Cardiovasc Interv 2009 Aug; 2 (4): 330-8
45. Mehilli J, Kastrati A, Schulz S, et al. Abciximab in patients with acute ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention after clopidogrel loading: a randomized double-blind trial. Circulation 2009 Apr 14; 119 (14): 1933-40
46. Kastrati A, Mehilli J, Neumann FJ, et al. Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial. JAMA 2006 Apr 5; 295 (13): 1531-8
47. Valgimigli M, Campo G, de Cesare N, et al. Intensifying platelet inhibition with tirofiban in poor responders to aspirin, clopidogrel, or both agents undergoing elective coronary intervention: results from the double-blind, prospective, randomized Tailoring Treatment with Tirofiban in Patients Showing Resistance to Aspirin and/or Resistance to Clopidogrel study. Circulation 2009 Jun 30; 119 (25): 3215-22
48. Hamm C, van 't Hof AW, ten Berg J, et al. Results of the On-TIME 2 trial: prehospital tirofiban in STEMI [abstract no. 413-5]. American College of Cardiology 57th Annual Scientific Sessions; 2008 Mar 29-Apr 1; Chicago (IL)
49. Braunwald E. Myocardial reperfusion, limitation of infarct size, reduction of left ventricular dysfunction, and improved survival: should the paradigm be expanded? Circulation 1989 Feb; 79: 441-4 (Pubitemid 19055515)
50. Ndrepepa G, Mehilli J, Schwaiger M, et al. Prognostic value of myocardial salvage achieved by reperfusion therapy in patients with acute myocardial infarction. JNucl Med 2004 May; 45 (5): 725-9 (Pubitemid 47618548)
51. Gersh BJ, Stone GW, White HD, et al. Pharmacological facilitation of primary percutaneous coronary intervention for acute myocardial infarction: is the slope of the curve the shape of the future? JAMA 2005 Feb 23; 293 (8): 979-86 (Pubitemid 40271130)
52. Francone M, Bucciarelli-Ducci C, Carbone I, et al. Impact of primary coronary angioplasty delay on myocardial salvage, infarct size, and microvascular damage in patients with ST-segment elevation myocardial infarction: insight from cardiovascular magnetic resonance. J Am Coll Cardiol 2009 Dec 1; 54 (23): 2145-53
53. Geeganage C, Wilcox R, Bath PM. Triple antiplatelet therapy for preventing vascular events: a systematic review and meta-analysis. BMC Med 2010 Jun 16; 8: 36
54. EPISTENT Investigators. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. Lancet 1998; 352: 87-92
55. The ESPRIT Study Group. Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial. Lancet 2006; 367: 1665-73
56. Kandzari DE, Berger PB, Kastrati A, et al. Influence of treatment duration with a 600-mg dose of clopidogrel before percutaneous coronary revascularization. J Am Coll Cardiol. 2004 Dec 7; 44 (11): 2133-6 (Pubitemid 39576031)
57. Campo G, Valgimigli M, Frangione A, et al. Evaluation of platelet inhibition by tirofiban in patients stratified according to aspirin and clopidogrel responsiveness: the 3T/2R (tailoring treatment with tirofiban in patients showing resistance to aspirin and/or resistance to clopidogrel). J Am Coll Cardiol 2010 Jan 19; 55 (3): 255-6
58. Valgimigli M, Biondi-Zoccai G, Tebaldi M, et al. Tirofiban as adjunctive therapy for acute coronary syndromes and percutaneous coronary intervention: a meta-analysis of randomized trials. Eur Heart J 2010 Jan; 31 (1): 35-49
59. Valgimigli M, Tebaldi M. Safety evaluation of tirofiban. Expert Opin Drug Saf 2010 Sep; 9 (5): 801-19
60. Giugliano RP, White JA, Bode C, et al. Early versus delayed, provisional eptifibatide in acute coronary syndromes. N Engl J Med 2009 May 21; 360 (21): 2176-90
61. Wang TY, White JA, Tricoci P, et al. Upstream clopidogrel use and the efficacy and safety of early eptifibatide treatment in patients with acute coronary syndrome: an analysis from the Early Glycoprotein IIb/IIIa Inhibition in Patients with Non-ST-Segment Elevation Acute Coronary Syndrome (EARLY ACS) trial. Circulation 2011 Feb 22; 123 (7): 722-30
62. O'Donoghue M, Antman EM, Braunwald E, et al. The efficacy and safety of prasugrel with and without a glycoprotein IIb/IIIa inhibitor in patients with acute coronary syndromes undergoing percutaneous intervention: a TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis In Myocardial Infarction 38) analysis. J Am Coll Cardiol 2009 Aug; 54: 678-85